---
title: $5.1M in UTHR Stock Sold by CEO Martine Rothblatt Days After Phase III Trial Results — A Billion-Dollar Seller Trims Again
type: news
slug: rothblatt-uthr-ceo-5m-sale-post-trial-results
canonical_url: https://13finsight.com/news/rothblatt-uthr-ceo-5m-sale-post-trial-results
published_at: 2026-03-17T18:39:33.153Z
updated_at: 2026-03-23T07:02:06.858Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 602
locale: en
source: 13F Insight
---

# $5.1M in UTHR Stock Sold by CEO Martine Rothblatt Days After Phase III Trial Results — A Billion-Dollar Seller Trims Again

> United Therapeutics CEO Martine Rothblatt sold $5.1 million in UTHR shares across March 12 and 16, 2026, bringing her career insider sales past $1 billion — just days after the ADVANCE OUTCOMES Phase III results and a Leerink conference appearance.

Martine Rothblatt, Chairperson and CEO of United Therapeutics Corporation (NASDAQ: UTHR), sold approximately $5.1 million in company stock across two trading days — March 12 and March 16, 2026. The sales came just days after the company discussed ADVANCE OUTCOMES Phase III clinical trial results on March 2 and presented at the Leerink Global Healthcare Conference on March 9. With these transactions, Rothblatt's career insider sales now exceed $1.05 billion. Transaction Breakdown The March sales involved an option exercise followed by multiple open-market dispositions at prices ranging from $534 to $544 per share: DateTypeSharesPriceValue 2026-03-16Sale516$534.99$276,065 2026-03-12Exercise9,500$146.03$1,387,285 2026-03-12Sale164$544.58$89,311 2026-03-12Sale356$543.22$193,386 2026-03-12Sale600$542.33$325,398 2026-03-12Sale400$541.31$216,524 2026-03-12Sale1,240$539.82$669,377 2026-03-12Sale720$538.94$388,037 On March 12, Rothblatt exercised 9,500 options at $146.03 per share and immediately sold 3,480 shares at prices between $538.94 and $544.58 — a classic exercise-and-sell pattern. Four days later, she sold an additional 516 shares at $534.99. The combined sale proceeds totaled roughly $5.1 million, net of the exercise cost. Why Now? Phase III Momentum and Conference Season The timing of these sales aligns with a period of heightened visibility for UTHR: March 2, 2026 — United Therapeutics discussed results from the ADVANCE OUTCOMES Phase III clinical trial, a key catalyst for the company's pulmonary arterial hypertension (PAH) franchise. March 9, 2026 — Rothblatt presented at the Leerink Global Healthcare Conference, outlining the company's growth trajectory and pipeline progress. Revenue momentum — The company reported over $3 billion in revenue for 2025, driven by continued Tyvaso growth, and management has targeted a $4 billion revenue run rate by 2027. Selling shortly after major corporate events is not unusual for systematic insiders — the sales likely occurred within a pre-planned trading window following the company's quiet period. The Career Pattern: $1.05 Billion in Sales — But Not an Exit With 6,319 career transactions on file, Martine Rothblatt is one of the most prolific insider sellers tracked on 13F Insight. Her cumulative sell volume of $1.05 billion dwarfs her $15.1 million in career purchases — a ratio that might alarm casual observers. But context matters. According to an SC 13G/A filing dated February 14, 2024, Rothblatt holds 7.8% beneficial ownership in United Therapeutics. This includes shares held directly and through affiliated entities. The 8,414 shares reported on her latest Form 4 represent only her direct holdings — not her full economic stake in the company. This is the profile of a systematic seller who remains deeply invested. Rothblatt has been trimming her position for years through regular option exercises and sales, a pattern consistent with diversification rather than a loss of conviction. Her beneficial ownership percentage — nearly 8% of a company with a market cap exceeding $15 billion — represents a stake worth well over a billion dollars. Key Facts MetricValue Career transactions6,319 Career sell volume$1.05 billion Career buy volume$15.1 million Direct shares (Form 4)8,414 Beneficial ownership (13G)7.8% RoleChairperson & CEO What to Watch For investors tracking UTHR, several catalysts remain on the horizon: ADVANCE OUTCOMES data readouts — Full Phase III results and potential regulatory submissions for expanded PAH indications. Tresmi and super prostacyclin pipeline — Next-generation therapies that could extend United Therapeutics' PAH franchise beyond Tyvaso. IPF program progress — The idiopathic pulmonary fibrosis pipeline represents a significant TAM expansion opportunity. $4 billion revenue target — Management's 2027 revenue run-rate goal will be a key benchmark in upcoming quarterly reports. Continued insider selling cadence — Whether Rothblatt maintains her systematic selling pattern or pauses could signal shifting confidence levels. Major institutional holders including Vanguard Group and Capital World Investors have maintained significant positions in UTHR, providing institutional backing alongside the CEO's ongoing — if gradually reduced — stake.

---

Source: 13F Insight — https://13finsight.com/news/rothblatt-uthr-ceo-5m-sale-post-trial-results
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-03-23T07:02:06.858Z